Why the study?
Does antihypertensive drug treatment (hydralazine, hexamethonium) aggravate angina pectoris in hypertensive patients with coronary artery disease?
Does antihypertensive drug treatment (hydralazine, hexamethonium) aggravate angina pectoris in hypertensive patients with coronary artery disease?
Certain antihypertensive drugs, such as hydralazine and hexamethonium, can paradoxically aggravate angina pectoris in patients with concurrent hypertension and coronary artery disease.
Alerts clinicians to potential angina worsening with specific antihypertensives; leaves open relevance for contemporary agents.
Antihypertensive drug treatment is capable of aggravating angina pectoris in hypertensive patients with coronary artery disease. The complication appears to be due to different hemodynamic mechanisms. Angina pectoris caused by hydralazine may result not only from a reduction in aortic perfusion pressure but also from increases in cardiac output and pulse rate which the drug produces. Coronary insufficiency, after the administration of hexamethonium, is usually associated with severe hypotension and results primarily from a reduction in aortic perfusion pressure. Hexamethonium was not found to prevent the anginal effects of hydralazine. Intravenous hydralazine is a sensitive test for coronary insufficiency but is not without untoward reactions.
No takes yet. Share an insight, caveat, or question.
Judson et al. (1956) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: